Protocol Ledger

NCT04332822 · Phase III · RECRUITING

A Randomized, Multicenter, Phase III Trial Comparing Treatment With R-mini-CHOP With R-mini-CHP + Polatuzumab Vedotin in Patients With Diffuse Large Cell B Cell Lymphoma

Interventional Phase III clinical trial protocol NCT04332822 sponsored by Nordic Lymphoma Group in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-08-19 Enrollment: 300 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT04332822
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)300 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04332822
Protocol FieldVerified Registry Value
NCT IdentifierNCT04332822
Consolidated Lead SponsorNordic Lymphoma Group
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment300 participants (ESTIMATED)
Registered Start Date2020-08-19
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04332822
Hospital Research SiteLocationSite Profile
Royal Prince Alfred HospitalCamperdown, AustraliaOpen Hospital Dossier ->
Concord Repatriation General HospitalConcord, AustraliaOpen Hospital Dossier ->
Royal Hobart HospitalHobart, AustraliaOpen Hospital Dossier ->
Fiona Stanley HospitalMurdoch, AustraliaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI